Three early phase clinical trials of DC vaccines in TNBC are currently in early stages, one using DC vaccine loaded with neo-antigen peptide, a second using DC loaded with WT1 and cyclin B1 antigens, and a third using DC vaccine targeting HER2/HER3 antigens with pembrolizumab in breast cancer patients with brain metastasis (Table 1). This evidence concerns the gene ERBB2 and breast cancer.